rMVAs
Experimental COVID-19 virus-vectored vaccines.
General information
rMVAs is a group of experimental vaccines based on modified vaccinia virus Ankara (replication-restricted viral system) encoding wild type or recombinant SARS-CoV-2 Spike protein variants (Liu et al., 2021).
Synonyms
Recombinant modified vaccinia virus Ankara (vaccines)
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection
Spike protein Viral vector Animal model In vitro Mixed substance |
in vitro binding assay; BALB/c mice; C57BL/6 mice; B6.Cg-Tg(K18-ACE2)2Prlmn/J mice; SARS-CoV-2 strain CoV-2 USA-WA1/2019 | 9.41 | The vaccines (one or two doses) induced IgG2a and IgG2c anti-Spike (SARS-CoV-2) antibodies, neutralizing antibodies, and CD3+CD8+IFNγ+ T Cells. Immunized K18-hACE2 mice were protected in a SARS-CoV-2 challenge (based on observations of weight loss, lung and nasal turbinate viral titres, and proinflammatory cytokine levels). RBD of Spike protein (adjuvanted) alone was able to potently boost antibody responses after a single rMVA vaccination. Results for different vaccine constructs varied and some of the experiments were performed only on smaller subsets of the vaccine variants. |
Mar/09/2021 |
